Literature DB >> 33652852

High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology.

Giorgio Napodano1, Matteo Ferro2, Roberto Sanseverino1.   

Abstract

Prostate cancer (PCa) is the most common cancer in males and affects 16% of men during their lifetime [...].

Entities:  

Year:  2021        PMID： 33652852      PMCID： PMC7996958          DOI： 10.3390/diagnostics11030400

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN： 2075-4418


  42 in total

1.  Contemporary management of men with high-risk localized prostate cancer in the United States.

Authors:  A B Weiner; R S Matulewicz; E M Schaeffer; S L Liauw; J M Feinglass; S E Eggener
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-06-20       Impact factor: 5.554

2.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Authors:  W James Morris; Scott Tyldesley; Sree Rodda; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-24       Impact factor: 7.038

3.  Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.

Authors:  Jochen Walz; Steven Joniau; Felix K Chun; Hendrik Isbarn; Claudio Jeldres; Ofer Yossepowitch; Hsu Chao-Yu; Eric A Klein; Peter T Scardino; Alwyn Reuther; Hein Van Poppel; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2010-09-28       Impact factor: 5.588

4.  Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.

Authors:  Israel Deutsch; Michael J Zelefsky; Zhigang Zhang; Qianxing Mo; Marco Zaider; Gil'ad Cohen; Oren Cahlon; Yoshiya Yamada
Journal:  Brachytherapy       Date:  2010-08-04       Impact factor: 2.362

5.  Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Authors:  Abdenour Nabid; Nathalie Carrier; André-Guy Martin; Jean-Paul Bahary; Céline Lemaire; Sylvie Vass; Boris Bahoric; Robert Archambault; François Vincent; Redouane Bettahar; Marie Duclos; Marie-Pierre Garant; Luis Souhami
Journal:  Eur Urol       Date:  2018-07-03       Impact factor: 20.096

6.  ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Authors:  Sree Rodda; W James Morris; Jeremy Hamm; Graeme Duncan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-21       Impact factor: 7.038

7.  Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Authors:  Colleen A F Lawton; Xiaolei Lin; Gerald E Hanks; Herbert Lepor; David J Grignon; Harmar D Brereton; Meena Bedi; Seth A Rosenthal; Kenneth L Zeitzer; Varagur M Venkatesan; Eric M Horwitz; Thomas M Pisansky; Harold Kim; Matthew B Parliament; Rachel Rabinovitch; Mack Roach; Young Kwok; James J Dignam; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-12       Impact factor: 7.038

8.  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Authors:  Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin
Journal:  Eur Urol       Date:  2012-08-10       Impact factor: 20.096

9.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Authors:  Luca Incrocci; Ruud C Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; Erik Schimmel; Stijn Krol; Peter-Paul van der Toorn; Hanja de Jager; Wilma Heemsbergen; Ben Heijmen; Floris Pos
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

10.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.